Anumana and Novartis Ink Software Development Deal

Mayo Clinical spinoff Anumana has entered into a multi-year collaboration with Novartis to develop artificial intelligence (AI)-powered software tools to detect cardiovascular conditions from electrocardiograms (ECGs).

The companies aim to develop a digital point-of-care tool that can be used to optimize medical therapies to reduce the risk of potentially avoidable hospitalizations and cardiovascular death.

The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret, the companies said.

The financial terms of the deal were not disclosed.